Novel Treatment Strategies for Patients with HER2-positive Breast Cancer Who Do Not Benefit from Current Targeted Therapy Drugs

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2018 Sep 7

PMID 30186457

Citations 11

Authors

Nan Jiang

Jing-Jing Lin

Jun Wang

Bei-Ning Zhang

Ao Li

Zheng-Yang Chen

Song Guo

Bin-Bin Li

Yu-Zhong Duan

Ru-Yi Yan

Hong-Feng Yan

Xiao-Yan Fu

Jin-Lian Zhou

He-Ming Yang

Yan Cui

Affiliations

Soon will be listed here.

Abstract

Human epidermal growth factor receptor-2 positive breast cancer (HER2 BC) is characterized by a high rate of metastasis and drug resistance. The advent of targeted therapy drugs greatly improves the prognosis of HER2 BC patients. However, drug resistance or severe side effects have limited the application of targeted therapy drugs. To achieve more effective treatment, considerable research has concentrated on strategies to overcome drug resistance. Abemaciclib (CDK4/6 inhibitor), a new antibody-drug conjugate (ADC), src homology 2 (SH2) containing tyrosine phosphatase-1 (SHP-1) and fatty acid synthase (FASN) have been demonstrated to improve drug resistance. In addition, using an effective vector to accurately deliver drugs to tumors has shown good application prospects. Many studies have also found that natural anti-cancer substances produced effective results during and anti-HER2 BC research. This review aimed to summarize the current status of potential clinical drugs that may benefit HER2 BC patients in the future.

Citing Articles

Assessment of the Efficacy and Pulmonary Toxicity of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer in a Tertiary Center in the United Arab Emirates.

Hourani M, Bdair R, Dawoud E, Trad D, Giridharan S, Al Qawasmeh K Cureus. 2025; 17(2):e78471.

PMID: 40062154 PMC: 11885178. DOI: 10.7759/cureus.78471.

HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.

Xu L, Xie Y, Gou Q, Cai R, Bao R, Huang Y Front Pharmacol. 2024; 15:1446414.

PMID: 39351085 PMC: 11439691. DOI: 10.3389/fphar.2024.1446414.

Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka.

Gunasekara A, Youngkong S, Anothaisintawee T, Dejthevaporn T, Fernandopulle R, Chaikledkaew U Sci Rep. 2024; 14(1):16736.

PMID: 39033229 PMC: 11271297. DOI: 10.1038/s41598-024-67598-2.

Neratinib for HER2-positive breast cancer with an overlooked option.

Guo L, Shao W, Zhou C, Yang H, Yang L, Cai Q Mol Med. 2023; 29(1):134.

PMID: 37803271 PMC: 10559443. DOI: 10.1186/s10020-023-00736-0.

HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via Induction.

Clayton N, Carter E, Fearon A, Heward J, Rodriguez Fernandez L, Boughetane L Int J Mol Sci. 2023; 24(7).

PMID: 37047202 PMC: 10094256. DOI: 10.3390/ijms24076228.

References

Baselga J, Gelmon K, Verma S, Wardley A, Conte P, Miles D . Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28(7):1138-44. PMC: 4979216. DOI: 10.1200/JCO.2009.24.2024. View

Jankowitz R, Abraham J, Tan A, Limentani S, Tierno M, Adamson L . Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol. 2013; 72(6):1205-12. DOI: 10.1007/s00280-013-2262-2. View

Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S . Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treat Rev. 2017; 57:8-15. DOI: 10.1016/j.ctrv.2017.04.005. View

Goel S, Wang Q, Watt A, Tolaney S, Dillon D, Li W . Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016; 29(3):255-269. PMC: 4794996. DOI: 10.1016/j.ccell.2016.02.006. View

Keyvanjah K, DiPrimeo D, Li A, Obaidi M, Swearingen D, Wong A . Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects. Br J Clin Pharmacol. 2016; 83(3):554-561. PMC: 5306479. DOI: 10.1111/bcp.13132. View

Xu Z, Zhang Y, Li N, Liu P, Gao L, Gao X . Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2017; 7(3):e013053. PMC: 5353336. DOI: 10.1136/bmjopen-2016-013053. View

Singh J, Jhaveri K, Esteva F . HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014; 111(10):1888-98. PMC: 4229628. DOI: 10.1038/bjc.2014.388. View

Tsou H, Overbeek-Klumpers E, Hallett W, Reich M, Floyd M, Johnson B . Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem. 2005; 48(4):1107-31. DOI: 10.1021/jm040159c. View

Choi Y, Li X, Hydbring P, Sanda T, Stefano J, Christie A . The requirement for cyclin D function in tumor maintenance. Cancer Cell. 2012; 22(4):438-51. PMC: 3487466. DOI: 10.1016/j.ccr.2012.09.015. View

10.

Petrelli F, Tomasello G, Barni S, Lonati V, Passalacqua R, Ghidini M . Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. Breast Cancer Res Treat. 2017; 166(2):339-349. DOI: 10.1007/s10549-017-4419-x. View

11.

Namjoshi P, Showalter L, Czerniecki B, Koski G . T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells. Oncotarget. 2019; 10(57):6006-6020. PMC: 6800266. DOI: 10.18632/oncotarget.10298. View

12.

Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen P, Sotiriou C . Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. Cancer Res. 2016; 76(2):264-74. DOI: 10.1158/0008-5472.CAN-15-1567. View

13.

Chandrika B, Steephan M, Santhosh Kumar T, Sabu A, Haridas M . Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors. Life Sci. 2016; 160:47-56. DOI: 10.1016/j.lfs.2016.07.007. View

14.

Hou Y, Nitta H, Wei L, Banks P, Parwani A, Li Z . Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy. Clin Breast Cancer. 2017; 18(2):e237-e244. PMC: 7219558. DOI: 10.1016/j.clbc.2017.11.001. View

15.

Blackwell K, Pegram M, Tan-Chiu E, Schwartzberg L, Arbushites M, Maltzman J . Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009; 20(6):1026-31. DOI: 10.1093/annonc/mdn759. View

16.

Blackwell K, Burstein H, Storniolo A, Rugo H, Sledge G, Koehler M . Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28(7):1124-30. DOI: 10.1200/JCO.2008.21.4437. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Menendez J, Lupu R . Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opin Ther Targets. 2017; 21(11):1001-1016. DOI: 10.1080/14728222.2017.1381087. View

19.

Tian C, Ding P, Yuan Z, Li H, Zhao Y, Sun L . A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells. Apoptosis. 2015; 20(12):1599-612. DOI: 10.1007/s10495-015-1164-7. View

20.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K . Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013; 4(10):1592-605. PMC: 3858548. DOI: 10.18632/oncotarget.1148. View